Abstracts tagged "autoimmune diseases"

Abstract Number: 0066 • ACR Convergence 2023
Mitochondrial Dysfunction and Fatigue in Sjögren’s Disease
Biji T Kurien¹, Rebecca Wood², Gavin Pharaoh³, Joshua Cavett¹, Valerie Lewis¹, Bhaskaran Shylesh¹, Lida radfar¹, Astrid Rasmussen¹, Christopher Lessard¹, A. Darise Farris¹, Kathy Sivils⁴, Kristi Koelsch¹, Holly Van Remmen¹ and R Hal Scofield⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Edmond, OK, ³University of Washington, Seattle, WA, ⁴Janssen Research & Development, LLC, Edmond, OK, ⁵Oklahoma City Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Sjögren's disease (SjD) is a chronic, autoimmune condition with diminished lacrimal and salivary gland secretion leading to keratoconjunctivitis sicca and xerostomia, respectively. In addition,…
Abstract Number: 0123 • ACR Convergence 2023
Improving Interpretation of Work Outcomes in Patients with Inflammatory Rheumatic Musculoskeletal Disease: General Population Reference Curves for Work Ability and At-work Productivity
Dafne Capelusnik¹, Wouter Smeets², Casper Webers³, Sofia Ramiro⁴, Elena Nikiphorou⁵, Roel Braekers², Laura Boekel⁶, Gertjan Wolbink⁷ and Annelies Boonen⁸, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Data science institute, Hasselt University, Hasselt, Belgium, ³Maastricht University, Maastricht, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵King's College London, London, United Kingdom, ⁶Amsterdam Rheumatology and Immunology Center, Location Reade, Department of Rheumatology, Amsterdam, Netherlands, ⁷Reade, Amsterdam, Netherlands, ⁸Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands
Background/Purpose: Data on self-reported presenteeism (limitations or reduced work productivity at work) in persons with inflammatory rheumatic and musculoskeletal diseases (iRMD) are challenging to interpret…
Abstract Number: 0253 • ACR Convergence 2023
Clinical Phenotypes in Patients with Isolated Anti-Sm/RNP Common Motif Antibody Positivity, Compared to Those with or Without Associated Anti-RNP Antibody Reactivity
Ruoning Ni¹ and Petar Lenert², ¹University of Iowa Hospitals and Clinics, Coralville, IA, ²University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: Anti-ribonucleoprotein (RNP) and anti-Sm/RNP common motif antibodies play a critical role in diagnosing patients with systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD)…
Abstract Number: 0468 • ACR Convergence 2023
Patients with Autoimmune Skin Diseases Are at Increased Risk of Adverse Pregnancy Outcomes
Heejo Keum¹, Bonnie Bermas², Shivani Patel¹, Benjamin Chong¹ and Heidi Jacobe¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX
Background/Purpose: Increased rates of adverse pregnancy outcomes (APOs) have been reported in association with rheumatologic diseases such as systemic lupus erythematosus (SLE), dermatomyositis (DM), and…
Abstract Number: 0666 • ACR Convergence 2023
Troponin I Levels in Systemic Sclerosis Patients with Myocardial Involvement
Eva Hoekstra¹, Sophie Liem¹, Nivine Levarht¹, Cynthia Fehres¹, Saad Ahmed¹, Nina Ajmone Marsan², Thomas Huizinga¹ and Jeska de Vries-Bouwstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Cardiology, Heart Lung Centre, Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: As primary myocardial involvement in systemic sclerosis (SSc) is associated with worse prognosis, research on diagnostic tools for recognition is essential. Troponin I was…
Abstract Number: 0926 • ACR Convergence 2023
Single-cell Multi-Omic Evaluation of Differences in Immune Cell Populations in Progression Toward Systemic Lupus Erythematosus
Aleksandra Bylinska, Miles Smith, Samantha Slight-Webb, Carla Guthridge, Caleb Marlin, Kevin Thomas, Christian Wright, Marci Beel, Susan Macwana, Wade DeJager, Judith James and Joel Guthridge, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Several groups of individuals are at higher risk for SLE, including those with African American ancestry (AA), lupus-associated autoantibodies (ANA+), or some clinical symptoms…
Abstract Number: 1066 • ACR Convergence 2023
Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab Pegol, in 63,930 Patient Samples
Kelly Chun and Jane Yang, Labcorp, Calabasas, CA
Background/Purpose: Biologic therapeutic drug monitoring (TDM) of TNF-inhibitor drug and anti-drug antibody provides patient-specific pharmacokinetic and immunogenic assessment. In suboptimal response, drug and anti-drug antibody…
Abstract Number: 1222 • ACR Convergence 2023
The Association Between Gingival Inflammation and Clinical Signs of Active Juvenile Dermatomyositis (JDM)
Albert Chow¹, Hyun Song², Laurie Brenchley³, Nastaran Bayat⁴, Mary Eckert⁵, Sean Koester⁶, adam Schiffenbauer⁷, Rita Volochayev⁷, Pamela Gardner³, Peggy Lee⁸, Jeffrey McLean⁹, Susan Shenoi¹⁰, Lisa Rider¹¹, Anne Stevens¹² and Neelendu Dey¹³, ¹Loma Linda University, Loma Linda, CA, ²Department of Dentistry, Seattle Children's Hospital, Seattle, WA, ³Office of the Clinical Director, NIDCR, National Institutes of Health, Bethesda, MD, ⁴Social Scientific Systems, DLH Holdings Corp, Silver Spring, MD, ⁵Center for Clinical and Translational Research, Seattle Children’s Research Institute, Seattle, WA, ⁶Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, ⁷Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁸Department of Oral Medicine, School of Dentistry, University of Washington, Seattle, WA, ⁹Department of Periodontics, University of Washington, Seattle, WA, ¹⁰Seattle Childrens Hospital, Mercer Island, WA, ¹¹NIEHS, NIH, Bethesda, MD, ¹²Janssen, Hansville, WA, ¹³Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, WA
Background/Purpose: JDM is a rare vasculopathy of unknown etiology characterized by typical rashes and proximal weakness. JDM has been associated with gingivitis, which can be…
Abstract Number: 1498 • ACR Convergence 2023
First-in-Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DS-7011a, an Anti-TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Giorgio Senaldi¹, Aparna Mohan¹, Li Zhang¹, Jun Tanaka², Grishma Pandya³, Sindee Grossman³, Sarah Urbina⁴, Steven Reynolds⁵ and Alan Hand⁴, ¹Daiichi Sankyo, Basking Ridge, NJ, ²Daiichi Sankyo, Inc., Basking Ridge, NJ, ³Daiichi Sankyo Inc., Basking Ridge, NJ, ⁴Worldwide Clinical Trials, San Antonio, TX, ⁵Cenexel, Los Alamitos, CA
Background/Purpose: Toll-like receptor (TLR)7 is a pattern recognition receptor, whose ligands include nucleic acids and whose activation is part of the pathogenesis of systemic lupus…
Abstract Number: 1690 • ACR Convergence 2023
Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients with Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study
Mikkel Østergaard¹, Walter P. Maksymowych², Mikael Boesen³, Robert Lambert⁴, Guillermo Valenzuela⁵, Michael Bubb⁶, Olga Kubassova⁷, Jyotsna Reddy⁸, Stephen Colgan⁹, Yuri Klyachkin¹⁰, Cynthia Deignan¹¹, Lihua Tang⁸, Maria Paris⁸ and Philip J. Mease¹², ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ²University of Alberta, Edmonton, AB, Canada, ³Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Naerum, Denmark, ⁴Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ⁵Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁶University of Florida, Gainesville, FL, ⁷Image Analysis Group, Philadelphia, PA, ⁸Amgen, Inc., Thousand Oaks, CA, ⁹Amgen, Inc., Halton Hills, ON, Canada, ¹⁰Amgen, Inc., Lexington, KY, ¹¹Amgen, Inc., Agoura Hills, CA, ¹²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: PsA is characterized by inflammatory arthritis, enthesitis, dactylitis, and spondylitis. Apremilast (APR) is an oral immunomodulating phosphodiesterase-4 inhibitor approved for the treatment of PsA.…
Abstract Number: 1884 • ACR Convergence 2023
Which Cell Pattern in Immunological Bronchoalveolar Lavage (BAL) Is Associated with a High-resolution Computer Tomography (HRCT) Pattern at the Onset of Inflammatory Rheumatic Disease with Interstitial Lung Disease?
tobias Hoffmann¹, Martin Förster², Peter Oelzner¹, Claus Kroegel², Ulf Teichgräber³, Diane Renz⁴, Joachim Böttcher¹, Christian Schulze², Gunter Wolf¹, Marcus Franz² and Alexander Pfeil¹, ¹Department of Internal Medicine III, Jena University Hospital – Friedrich Schiller University Jena, Jena, Germany, ²Department of Internal Medicine I, Jena University Hospital – Friedrich Schiller University Jena, Jena, Germany, ³Institute of Diagnostic and Interventional Radiology, Jena University Hospital – Friedrich Schiller University Jena, Jena, Germany, ⁴Institute of Diagnostic and Interventional Radiology, Department of Pediatric Radiology, Hannover Medical School, Hannover, Germany
Background/Purpose: Inflammatory rheumatic diseases (IRD) are associated with interstitial lung disease (ILD). High-resolution Computer Tomography (HRCT) is recommended as goldstandard in the detection of IRD-ILD.…
Abstract Number: 2019 • ACR Convergence 2023
2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases
Emma Dures¹, Bayram Farisogullari², Eduardo Santos³, Anna Molto⁴, Caroline Feldthusen⁵, Claire Harris⁶, Corinna Elling-Audersch⁷, Deirdre Conolly⁸, Elena Elefante⁹, Fernando Estévez-López¹⁰, Ilaria Bini¹¹, Jette Primdahl¹², Kirsten Hoeper¹³, Marie Urban¹⁴, Mart van de Laar¹⁵, Marta Redondo¹⁶, Peter Böhm¹⁷, Raj Amarnani¹⁸, Rhys Hayward⁶, Rinie Geenen¹⁹, Simona Rednic²⁰, Susanne Pettersson²¹, Tanja Thomsen²², Till Uhlig²³, Valentin Ritschl²⁴ and Pedro Machado²⁵, ¹Academic Rheumatology, Bristol Royal Infirmary; and Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra (ESEnfC), Coimbra, Portugal, ⁴HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁵Institute of Neuroscience and Physiology, University of Gothenburg, Department of Health and Rehabilitation, Unit of Physiotherapy, Sahlgrenska Academy, Gothenburg, Sweden, ⁶Northwick Park Hospital, London North West University Healthcare NHS Trust, Department of Rheumatology, London, United Kingdom, ⁷Deutsche Rheuma-Liga Bundesverband e.V., Patient Research Partner, Bonn, Germany, ⁸School of Medicine, Trinity College Dublin, Discipline of Occupational Therapy, Dublin, Ireland, ⁹Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ¹⁰Harvard T.H. Chan School of Public Health, Department of Social and Behavioral Sciences, Boston, MA, ¹¹Anmar, Young, Rome, Italy, Rome, Italy, ¹²University Hospital of Southern Denmark, Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ¹³Hannover Medical School, Department of Rheumatology and Immunology, Hannover, Germany, ¹⁴University Hospitals Bristol, Research Design Service, Bristol, United Kingdom, ¹⁵University of Twente, Department of Psychology, Health and Technology, Enschede, Netherlands, ¹⁶Camilo José Cela University, Faculty of Heath Sciences, Madrid, Spain, ¹⁷German League against rheumatism, Forschungspartner, Bonn, Germany, ¹⁸Barts Health NHS Trust, Barts Health Rheumatology Service, London, United Kingdom, ¹⁹Utrecht University, Vorstenbosch, Netherlands, ²⁰Prof Dr Simona Rednic, Cluj, Romania, ²¹Karolinska Institute, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ²²University of Copenhagen, Copenhagen Centre for Arthritis Research, Centre for Rheumatology and Spine Diseases VRR, Rigshospitalet, Copenhagen, Denmark, ²³Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²⁴Medical University of Vienna, Vienna, Austria, ²⁵Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom
Background/Purpose: Fatigue is prevalent in people with inflammatory rheumatic and musculoskeletal diseases (I-RMDs) and recognized as one of the most challenging symptoms to manage (1).…
Abstract Number: 2310 • ACR Convergence 2023
Machine Learning Approaches for Prediction of Renal Flares in Systemic Lupus Erythematosus: Knowledge-Driven Models Outperformed Data-Driven Models
Nursen Cetrez¹, Julius Lindblom¹, Raffaele Da Mutten², Dionysis Nikolopoulos² and Ioannis Parodis¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden
Background/Purpose: Renal flares in patients with SLE result in significant nephron loss. Thus, identification of reliable early signals of impending renal flares is anticipated to…
Abstract Number: 2518 • ACR Convergence 2023
Could the Adenosine Pathway Identify Cases with a Progressive Fibrosing Phenotype Between Patients with Autoimmune Interstitial Lung Disease? An Initial Approach
Olga Sanchez Pernaute¹, Cristina Vadillo-Font², Hilda Godoy³, Laura Cebrian⁴, Gema Bonilla⁵, Rosario Garcia-Vicuna⁶, Irene Llorente Cubas⁶, Fredeswinda Romero¹, Rosalía Laporta³, Belen Lopez-Muñiz⁴, M Asunción Nieto⁷, Luis Gomez-Carrera⁵, Claudia Valenzuela⁸, M Jesus Rodriguez-Nieto⁹ and lydia Abasolo¹⁰, ¹IIS-HU Fundación Jiménez Díaz, Madrid, Spain, ²Hospital Clinico San Carlos, Madrid, Spain, ³Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁴Hospital Universitario Infanta Leonor, Madrid, Spain, ⁵Hospital Univ. La Paz, Madrid, Spain, ⁶Hospital Universitario de la Princesa, Madrid, Spain, ⁷Hospital Clínico S. Carlos, Madrid, Spain, ⁸Hospital Universitario La Princesa, Madrid, Spain, ⁹Pulmonology department, Hospital Fundación Jimenez Díaz, Madrid, Spain, ¹⁰Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Interstitial lung diseases with an autoimmune background (AIP) are a heterogeneous group of processes. There is an unmet need to identify those cases with…
Abstract Number: 0068 • ACR Convergence 2023
Anti-TNFR2 VHH Agonistic Antibodies Promote and Stabilize Treg Immunosuppressive Activity
Lee Kim Swee¹, Julia Knopf¹, Tomasz Próchnicki¹, Paul-Albert König¹, Alexander Kirchhoff¹, Laura Preiß¹, Ferdinand Huber¹, Annegrit Seifried¹, Olga Murawjew¹, Fabienne Baumann¹, Jessica Assis¹, Sonja Hennemann¹, Felix Kolbe¹, Helena Schnell¹, Thomas Orlik¹, Kevin Blanco Valle¹, Alissa Telling², Brian Sanchez², Anthony Opipari², Tobias Stuwe¹, Stephen Soisson³ and Luigi Franchi², ¹Odyssey Therapeutics GmbH, Frankfurt am Main, Germany, ²Odyssey Therapeutics, Ann Arbor, MI, ³Odyssey Therapeutics, Boston, MA
Background/Purpose: Regulatory T cells (Treg) are a population of lymphocytes with immunosuppressive function. Activation and expansion of Treg is an attractive therapeutic approach for autoimmune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].